If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
There is no information on which to base a recommendation for a washout period for those who are receiving galcanezumab and are planning to become pregnant.
Clinicians should use their clinical judgment in determining the most appropriate approach in a patient treated with galcanezumab who is planning to become pregnant.
A galcanezumab pregnancy registry is currently under review with the United States Food and Drug Administration.
Pregnancy or related events can be reported to
The published reference below is available by contacting 1-800-LillyRx (1-800-545-5979).
1Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
2Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780
IgG = immunoglobulin G
IgG4 = immunoglobulin G (subclass) 4
t1/2 = elimination half-life
Date of Last Review: January 11, 2021